Tags

Type your tag names separated by a space and hit enter

Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
Respir Med. 2006 Sep; 100(9):1504-11.RM

Abstract

We compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design. A total of 563 patients with AECB were enrolled (437 efficacy-valid) at 34 centers in Mexico, Argentina, Brazil, Colombia, and Peru. Patients were randomized to oral therapy with either moxifloxacin 400 mg once daily for 5 days or levofloxacin 500 mg once daily for 7 days. Clinical success was achieved in 201 out of 221 (91.0%) patients in the moxifloxacin group, and in 203 out of 216 (94.0%) in the levofloxacin group, indicating that moxifloxacin is equivalently effective to levofloxacin. Bacteriologic eradication or presumed eradication was also similar in the two treatment groups: 92.8% in the moxifloxacin group and 93.8% in the levofloxacin group. Nausea was the most common drug-related adverse event in each treatment group. The rate of discontinuation because of adverse events was very low (2%). In conclusion, a 5-day course of moxifloxacin is clinically and bacteriologically equivalent to a 7-day course of levofloxacin in the treatment of patients with AECB. The short treatment duration with moxifloxacin may have compliance advantages over other currently used therapies in the 'real-life' clinical setting.

Authors+Show Affiliations

Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16504492

Citation

Urueta-Robledo, Juan, et al. "Moxifloxacin Versus Levofloxacin Against Acute Exacerbations of Chronic Bronchitis: the Latin American Cohort." Respiratory Medicine, vol. 100, no. 9, 2006, pp. 1504-11.
Urueta-Robledo J, Ariza H, Jardim JR, et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir Med. 2006;100(9):1504-11.
Urueta-Robledo, J., Ariza, H., Jardim, J. R., Caballero, A., García-Calderón, A., Amábile-Cuevas, C. F., Hernández-Oliva, G., & Vivar-Orozco, R. (2006). Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respiratory Medicine, 100(9), 1504-11.
Urueta-Robledo J, et al. Moxifloxacin Versus Levofloxacin Against Acute Exacerbations of Chronic Bronchitis: the Latin American Cohort. Respir Med. 2006;100(9):1504-11. PubMed PMID: 16504492.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. AU - Urueta-Robledo,Juan, AU - Ariza,Horacio, AU - Jardim,José R, AU - Caballero,Andrés, AU - García-Calderón,Andrés, AU - Amábile-Cuevas,Carlos F, AU - Hernández-Oliva,Gerardo, AU - Vivar-Orozco,Raul, AU - ,, Y1 - 2006/02/28/ PY - 2005/11/11/received PY - 2006/01/11/revised PY - 2006/01/19/accepted PY - 2006/3/1/pubmed PY - 2007/6/15/medline PY - 2006/3/1/entrez SP - 1504 EP - 11 JF - Respiratory medicine JO - Respir Med VL - 100 IS - 9 N2 - We compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design. A total of 563 patients with AECB were enrolled (437 efficacy-valid) at 34 centers in Mexico, Argentina, Brazil, Colombia, and Peru. Patients were randomized to oral therapy with either moxifloxacin 400 mg once daily for 5 days or levofloxacin 500 mg once daily for 7 days. Clinical success was achieved in 201 out of 221 (91.0%) patients in the moxifloxacin group, and in 203 out of 216 (94.0%) in the levofloxacin group, indicating that moxifloxacin is equivalently effective to levofloxacin. Bacteriologic eradication or presumed eradication was also similar in the two treatment groups: 92.8% in the moxifloxacin group and 93.8% in the levofloxacin group. Nausea was the most common drug-related adverse event in each treatment group. The rate of discontinuation because of adverse events was very low (2%). In conclusion, a 5-day course of moxifloxacin is clinically and bacteriologically equivalent to a 7-day course of levofloxacin in the treatment of patients with AECB. The short treatment duration with moxifloxacin may have compliance advantages over other currently used therapies in the 'real-life' clinical setting. SN - 0954-6111 UR - https://www.unboundmedicine.com/medline/citation/16504492/Moxifloxacin_versus_levofloxacin_against_acute_exacerbations_of_chronic_bronchitis:_the_Latin_American_Cohort_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(06)00044-8 DB - PRIME DP - Unbound Medicine ER -